Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yuxiang Dong is active.

Publication


Featured researches published by Yuxiang Dong.


Nature | 2004

Identification of an antimalarial synthetic trioxolane drug development candidate

Jonathan L. Vennerstrom; Sarah Arbe-Barnes; Reto Brun; Susan A. Charman; Francis Chi Keung Chiu; Jacques Chollet; Yuxiang Dong; Arnulf Dorn; Daniel Hunziker; Hugues Matile; Kylie Anne McIntosh; Maniyan Padmanilayam; Josefina Santo Tomas; Christian Scheurer; Bernard Scorneaux; Yuanqing Tang; Heinrich Urwyler; Sergio Wittlin; William N. Charman

The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. Available evidence suggests that artemisinin and related peroxidic antimalarial drugs exert their parasiticidal activity subsequent to reductive activation by haem, released as a result of haemoglobin digestion by the malaria-causing parasite. This irreversible redox reaction produces carbon-centred free radicals, leading to alkylation of haem and proteins (enzymes), one of which—the sarcoplasmic-endoplasmic reticulum ATPase PfATP6 (ref. 7)—may be critical to parasite survival. Notably, there is no evidence of drug resistance to any member of the artemisinin family of drugs. The chemotherapy of malaria has benefited greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have good therapeutic indices and provide for successful treatment outcomes. However, as a drug class, the artemisinins suffer from chemical (semi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pharmacokinetics) and treatment (non-compliance with long treatment regimens and recrudescence) issues that limit their therapeutic potential. Here we describe how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

Susan A. Charman; Sarah Arbe-Barnes; Ian Bathurst; Reto Brun; Michael Campbell; William N. Charman; Francis Chi Keung Chiu; Jacques Chollet; J. Carl Craft; Darren J. Creek; Yuxiang Dong; Hugues Matile; Melanie Maurer; Julia Morizzi; Tien Nguyen; Petros Papastogiannidis; Christian Scheurer; David M. Shackleford; Kamaraj Sriraghavan; Lukas Stingelin; Yuanqing Tang; Heinrich Urwyler; Xiaofang Wang; Karen L. White; Sergio Wittlin; Lin Zhou; Jonathan L. Vennerstrom

Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase IIa trials in malaria patients. Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clinical drug development candidate. In vitro, OZ439 is fast-acting against all asexual erythrocytic Plasmodium falciparum stages with IC50 values comparable to those for the clinically used artemisinin derivatives. Unlike all other synthetic peroxides and semisynthetic artemisinin derivatives, OZ439 completely cures Plasmodium berghei-infected mice with a single oral dose of 20 mg/kg and exhibits prophylactic activity superior to that of the benchmark chemoprophylactic agent, mefloquine. Compared with other peroxide-containing antimalarial agents, such as the artemisinin derivatives and the first-generation ozonide OZ277, OZ439 exhibits a substantial increase in the pharmacokinetic half-life and blood concentration versus time profile in three preclinical species. The outstanding efficacy and prolonged blood concentrations of OZ439 are the result of a design strategy that stabilizes the intrinsically unstable pharmacophoric peroxide bond, thereby reducing clearance yet maintaining the necessary Fe(II)-reactivity to elicit parasite death.


Antimicrobial Agents and Chemotherapy | 2007

In Vitro and In Vivo Activities of Synthetic Trioxolanes against Major Human Schistosome Species

Shu hua Xiao; Jennifer Keiser; Jacques Chollet; Jürg Utzinger; Yuxiang Dong; Yvette Endriss; Jonathan L. Vennerstrom; Marcel Tanner

ABSTRACT Schistosomiasis is a parasitic disease that remains of considerable public health significance in tropical and subtropical environments. Since the mainstay of schistosomiasis control is chemotherapy with a single drug, praziquantel, drug resistance is a concern. Here, we present new data on the antischistosomal properties of representative synthetic 1,2,4-trioxolanes (OZs). Exposure of adult Schistosoma mansoni for 24 h to a medium containing 20 μg/ml OZ209 reduced worm motor activity, induced tegumental alterations, and killed worms within 72 h. While exposure of S. mansoni to OZ78 had no apparent effect, addition of hemin reduced worm motor activity and caused tegumental damage. Administration of single 200-mg/kg of body weight oral doses of OZ78, OZ209, and OZ288 to mice harboring a juvenile S. mansoni infection resulted in worm burden reductions of 82.0 to 95.4%. In the adult infection model in mice, single 400-mg/kg doses of these compounds resulted in a maximum total worm burden reduction of 52.2%. High worm burden reductions (71.7 to 86.5%) were observed after administration of single 200-mg/kg doses of OZ78 and OZ288 to hamsters infected with either juvenile or adult S. mansoni. A single 200-mg/kg dose of OZ78 to hamsters infected with adult Schistosoma japonicum resulted in total and female worm burden reductions of 94.2 to 100%. Our results, along with the low toxicity, metabolic stability, and good pharmacokinetic properties of the OZs, indicate the potential for the development of novel broad-spectrum antischistosomal OZ drug candidates.


Antimicrobial Agents and Chemotherapy | 2008

Relationship between Antimalarial Activity and Heme Alkylation for Spiro- and Dispiro-1,2,4-Trioxolane Antimalarials

Darren J. Creek; William N. Charman; Francis Chi Keung Chiu; Richard John Prankerd; Yuxiang Dong; Jonathan L. Vennerstrom; Susan A. Charman

ABSTRACT The reaction of spiro- and dispiro-1,2,4-trioxolane antimalarials with heme has been investigated to provide further insight into the mechanism of action for this important class of antimalarials. A series of trioxolanes with various antimalarial potencies was found to be unreactive in the presence of Fe(III) hemin, but all were rapidly degraded by reduced Fe(II) heme. The major reaction product from the heme-mediated degradation of biologically active trioxolanes was an alkylated heme adduct resulting from addition of a radical intermediate. Under standardized reaction conditions, a correlation (R2 = 0.88) was found between the extent of heme alkylation and in vitro antimalarial activity, suggesting that heme alkylation may be related to the mechanism of action for these trioxolanes. Significantly less heme alkylation was observed for the clinically utilized artemisinin derivatives compared to the equipotent trioxolanes included in this study.


Journal of Medicinal Chemistry | 2010

The Structure−Activity Relationship of the Antimalarial Ozonide Arterolane (OZ277)

Yuxiang Dong; Sergio Wittlin; Kamaraj Sriraghavan; Jacques Chollet; Susan A. Charman; William N. Charman; Christian Scheurer; Heinrich Urwyler; Josefina Santo Tomas; Christopher Snyder; Darren J. Creek; Julia Morizzi; Maria Koltun; Hugues Matile; Xiaofang Wang; Maniyan Padmanilayam; Yuanqing Tang; Arnulf Dorn; Reto Brun; Jonathan L. Vennerstrom

The structure and stereochemistry of the cyclohexane substituents of analogues of arterolane (OZ277) had little effect on potency against Plasmodium falciparum in vitro. Weak base functional groups were not required for high antimalarial potency, but they were essential for high antimalarial efficacy in P. berghei-infected mice. Five new ozonides with antimalarial efficacy and ADME profiles superior or equal to that of arterolane were identified.


Antimicrobial Agents and Chemotherapy | 2007

Peroxide Bond-Dependent Antiplasmodial Specificity of Artemisinin and OZ277 (RBx11160)

Marcel Kaiser; Sergio Wittlin; Angela Nehrbass-Stuedli; Yuxiang Dong; Xiaofang Wang; Andrew Hemphill; Hugues Matile; Reto Brun; Jonathan L. Vennerstrom

ABSTRACT Using nonperoxidic analogs of artemisinin and OZ277 (RBx11160), the strong in vitro antiplasmodial activities of the latter two compounds were shown to be peroxide bond dependent. In contrast, the weak activities of artemisinin and OZ277 against six other protozoan parasites were peroxide bond independent. These data support the iron-dependent artemisinin alkylation hypothesis.


Journal of Medicinal Chemistry | 2013

Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres.

Xiaofang Wang; Yuxiang Dong; Sergio Wittlin; Susan A. Charman; Francis Chi Keung Chiu; Jacques Chollet; Kasiram Katneni; Janne Mannila; Julia Morizzi; Eileen Ryan; Christian Scheurer; Jessica Steuten; Josefina Santo Tomas; Christopher Snyder; Jonathan L. Vennerstrom

To ascertain the structure-activity relationship of the core 1,2,4-trioxolane substructure of dispiro ozonides OZ277 and OZ439, we compared the antimalarial activities and ADME profiles of the 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. Consistent with previous data, both dioxolanes had very weak antimalarial properties. For the OZ277 series, the trioxane isostere had the best ADME profile, but its overall antimalarial efficacy was not superior to that of the trioxolane or tetraoxane isosteres. For the OZ439 series, there was a good correlation between the antimalarial efficacy and ADME profiles in the rank order trioxolane > trioxane > tetraoxane. As we have previously observed for OZ439 versus OZ277, the OZ439 series peroxides had superior exposure and efficacy in mice compared to the corresponding OZ277 series peroxides.


Bioorganic & Medicinal Chemistry Letters | 2010

Praziquantel analogs with activity against juvenile Schistosoma mansoni.

Yuxiang Dong; Jacques Chollet; Mireille Vargas; Nuha R. Mansour; Q. D. Bickle; Yazen Alnouti; Jiangeng Huang; Jennifer Keiser; Jonathan L. Vennerstrom

Six amide and four urea derivatives of praziquantel were synthesized and tested for antischistosomal activity against juvenile and adults stages of Schistosoma mansoni in infected mice. Only one of these had significant activity against adult worms, but, unlike praziquantel, six of these had low to modest activity against juvenile worms. A praziquantel ketone derivative had the best combination of activity against juveniles and adults, but it had no effect on the motility of adult S. mansoni in ex vivo culture. Cytochrome P450 metabolic stability data support the hypothesis that the major trans-cyclohexanol metabolite of praziquantel plays an important role in the antischistosomal activity of this drug.


Antimicrobial Agents and Chemotherapy | 2012

In Vivo Activity of Aryl Ozonides against Schistosoma Species

Jennifer Keiser; Katrin Ingram; Mireille Vargas; Jacques Chollet; Xiaofang Wang; Yuxiang Dong; Jonathan L. Vennerstrom

ABSTRACT We evaluated the in vivo antischistosomal activities of 11 structurally diverse synthetic peroxides. Of all compounds tested, ozonide (1,2,4-trioxolane) OZ418 had the highest activity against adult Schistosoma mansoni, with total and female worm burden reductions of 80 and 90% (P < 0.05), respectively. Furthermore, treatment of S. haematobium-infected mice with OZ418 reduced the total worm burden by 86%. In conclusion, OZ418 is a promising antischistosomal lead compound.


Journal of Medicinal Chemistry | 2000

Methyl-substituted dispiro-1,2,4,5-tetraoxanes: correlations of structural studies with antimalarial activity.

Kevin J. McCullough; James K. Wood; Apurba K. Bhattacharjee; Yuxiang Dong; Dennis E. Kyle; Wilbur K. Milhous; Jonathan L. Vennerstrom

Two tetramethyl-substituted dispiro-1,2,4,5-tetraoxanes (7,8,15, 16-tetraoxadispiro[5.2.5.2]hexadecanes) 3 and 4 were designed as metabolically stable analogues of the dimethyl-substituted dispiro-1, 2,4,5-tetraoxane prototype WR 148999 (2). For a positive control we selected the sterically unhindered tetraoxane 5 (7,8,15, 16-tetraoxadispiro[5.2.5.2]hexadecane), devoid of any substituents. Tetraoxanes 3 and 4 were completely inactive in contrast to tetraoxanes 2 and 5. We hypothesize that the two inactive tetraoxanes possess sufficient steric hindrance about the tetraoxane ring due to the two additional axial methyl groups to prevent their activation to presumed parasiticidal carbon radicals by inhibiting electron transfer from heme or other iron(II) species. For each of the tetraoxanes 2-4, the tetraoxane and both spirocyclohexyl rings are in a chair conformation and the bond lengths and angles are all quite normal except for the C1-C2 bond which is slightly lengthened. Comparison of the modeled and X-ray structures for tetraoxanes 2-5 reveals that molecular mechanics (MMX and MM3) and 3-21G calculations each gave accurate structural parameters such as bond lengths, bond angles, and dihedral angles. In contrast, semiempirical methods such as AM1 gave poor results.

Collaboration


Dive into the Yuxiang Dong's collaboration.

Top Co-Authors

Avatar

Jonathan L. Vennerstrom

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Xiaofang Wang

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sergio Wittlin

Swiss Tropical and Public Health Institute

View shared research outputs
Top Co-Authors

Avatar

Susan A. Charman

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hugues Matile

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jennifer Keiser

Swiss Tropical and Public Health Institute

View shared research outputs
Top Co-Authors

Avatar

William N. Charman

Rensselaer Polytechnic Institute

View shared research outputs
Top Co-Authors

Avatar

Yuanqing Tang

University of Nebraska Medical Center

View shared research outputs
Top Co-Authors

Avatar

Christian Scheurer

Swiss Tropical and Public Health Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge